Fig. 7 | Scientific Reports

Fig. 7

From: ALKBH5 acts a tumor-suppressive biomarker and is associated with immunotherapy response in hepatocellular carcinoma

Fig. 7

Immunotherapy response evaluation of patients in the two subtypes. (A, B) Expression of immunostimulatory and immunoinhibitory genes in the two HCC subtypes. (C) Differences in TIDE score, IFNG and MSI in the two HCC subtypes. (D) Differences in T-cell dysfunction and exclusion in the two HCC subtypes based on the TIDE database. (E) Differences in MDSC of the two HCC subtypes. (F, G) Landscape of genomic mutations in the two HCC subtypes. (H) The expression of T-cell exhaustion markers in the two HCC subtypes. (I) The expression of key regulators in WNT/β-catenin signaling between the two HCC subtypes. (*P < 0.05, **P < 0.01, ***P < 0.001).

Back to article page